

## GEORGE DRANITSARIS

### PUBLICATIONS

1. Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. *Support Care Cancer* 2012 Apr 27.
2. Dranitsaris G, Jelincic V, Choe Y. Meta-Regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events. *Clinical and Applied Thrombosis and Hemostasis* 2012 Mar 2.
3. Dranitsaris G, Vincent M, Yu j, et al. Development and validation of a prediction index for hand foot skin reaction in cancer patients receiving sorafenib. *Annals of Oncology* 2012, Jan 6.
4. Dranitsaris G, Truter I, Lubbe MS. The development of a value based pricing index for new drugs in metastatic colorectal cancer. *European Journal of Cancer* 2011;47:1299-304.
5. Dranitsaris G, Amir E, Dorward K. Biosimilars of Protein Based Drug Therapies: Regulatory, Clinical and Commercial Considerations. *Drugs* 2011;71:1527-36.
6. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. *Supportive Care in Cancer* 2011 Jul 22.
7. Dranitsaris G, Jelincic V, Choe Y. Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement. *Thrombosis Journal* 2011;9:3
8. Dranitsaris G, Truter I, Lubbe M et al. Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. *International Journal of Technology Assessment in Health Care* 2011;27:23-30.
9. Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: A cost effectiveness analysis. *Supportive Care in Cancer* 2011;19:1807-13.
10. Dranitsaris G, Truter I, Lubbe M. The application of pharmacoeconomic modeling to estimate a value based price for new cancer drugs. *Journal of Evaluation in Clinical Practice* November 18, 2010.

11. Dranitsaris G, Truter I, Lubbe MS, et al. Advances in cancer therapeutics and patient access to new drugs. *Pharmacoeconomics* 2011;29:213-24.
12. Dranitsaris G, Edwards S, Edwards J, et al. Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: An assessment of safety and efficacy in the Canadian province of Newfoundland and Labrador. *Current Oncology* 2010;17:12-6.
13. Dranitsaris G, Joy A, Young S, et al. Identifying patients at high risk for nausea and vomiting after chemotherapy: The development of a practical prediction tool. *Journal of Supportive Oncology* 2009;7:W1-8.
14. Dranitsaris G, Coleman, Gradishar W. nab-paclitaxel weekly or Q3W compared to docetaxel Q3W as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. *Breast Cancer Research and Treatment* 2010;119:717-24.
15. Freedman O, Amir E, Dranitsaris G, et al. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. *Breast Cancer Research and Treatment* 2010;119:155-61.
16. Hatzimichael E, Dranitsaris G, Dasoula A et al. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. *Clinical Lymphoma and Myeloma* 2009;9:239-42.
17. Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. *Applied Health Economics and Health Policy* 2009;7:43-59.
18. Vincent MD, Dranitsaris G. The price function of toxicity. *Lancet Oncology* 2009;10:299-303.
19. Dranitsaris G, Selby P, Negrete, JC. Meta analysis of placebo controlled trials of acamprosate for the treatment of alcohol dependence. *Journal of Addiction Medicine* 2009;3:74-82.
20. Dranitsaris G, Stumpo C, Smith R and Bartle W. Cost-utility analysis of extended dalteparin prophylaxis for venous thromboembolic events in patients undergoing major orthopedic surgery. *American Journal of Cardiovascular Drugs* 2009;9:45-58.
21. Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. *Journal of Oncology Pharmacy Practice* 2009;15:67-78.
22. Dranitsaris G, Rayson D, Vincent M, et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: The development of a prediction model. *American Journal of Clinical Oncology* 2008;31:369-74.

23. Dranitsaris G, Rayson D, Vincent M, et al. The development of a prediction model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. *Breast Cancer Research and Treatment* 2008;107:443-50.
24. Stebbing J, Dranitsaris G, Vincent M. Chemotherapy-Induced Toxicity in the Community Oncology Setting: Hear No Evil, See No Evil. Editorial: *British Medical Journal* Dec 6; 2007.
25. Booth CM, Clemons M, Dranitsaris G et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. *Journal of Supportive Oncology* 2007;5:374-80.
26. Booth CM, Dranitsaris G, Gainford MC, et al. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. *BMC Cancer*. 2007 Jun 28;7:110.
27. Clemons M, Dranitsaris G, Ooi W, Cole DEC. A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event or progressive bone metastases despite standard bisphosphonate therapy. *Breast Cancer Research and Treatment* 2008;108:79-85.
28. Verma S, Wong NS, Trudeau M, Joy A, Mackey J, Dranitsaris G, Clemons M. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. *American Journal of Clinical Oncology* 2007;30:297-302.
29. Dranitsaris G, Shah A, Spirovski B, Vincent M. Severe diarrhea in patients with advanced colorectal Cancer receiving FOLFOX or FOLFIRI chemotherapy: development of a risk prediction tool. *Clinical Colorectal Cancer* 2007;6:367-73.
30. Vincent M, Dranitsaris G, Verma S et al. The development of a prediction tool for chemotherapy-induced anemia in patients with advanced non small cell lung cancer receiving palliative chemotherapy. *Supportive Care in Cancer* 2007;15:265-72.
31. Clemons M, Dranitsaris G, Ooi W, et al. A Phase II trial evaluating the palliative benefit of second line zoledronic acid in breast cancer patients with either a skeletal related event or progressive bone metastases despite first line bisphosphonate therapy. *Journal of Clinical Oncology* 2006;24:1-6.
32. Canadian Surgical Wait Times Initiative. Consensus document: Recommendations for optimal surgical wait times for patients with urological malignancies. *Canadian Journal of Urology* 2006;13: (suppl 3) 62-4.
33. Fleshner N, Dranitsaris G, Finelli A, et al. Surgical wait times for patients with urological cancers: A survey of Canadian surgeons. *Journal of Urology* 2006;13: (suppl 3) 3-13.

34. Dranitsaris G, Vincent M, Crowther M. Dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: A pharmacoeconomic analysis. *Pharmacoeconomics* 2006;24:593-607.
35. Dranitsaris G, Maroun J, Chiritescu G, et al. The development of a prediction tool for severe diarrhea in patients with colorectal cancer receiving chemotherapy. *Support and Palliative Cancer Care Journal* 2006;2:127-34.
36. Dranitsaris G, Clemons M, Verma S et al. The development of a prediction tool for anemia in breast cancer patients receiving adjuvant chemotherapy. *Lancet Oncology* 2005;6:856-63.
37. Dranitsaris G, Johnson M, Poirier S et al. Are health care providers who work with cancer drugs at an increased risk for toxic events?: A systematic review and meta analysis of the literature. *Journal of Oncology Pharmacy Practice* 2005;11:69-73.
38. Dranitsaris G, Milliken D, Zanke B, Evans WK. The impact of practice guidelines and funding policies on the uptake of new chemotherapy drugs for the treatment of advanced non-small cell lung cancer. *Journal of Evaluation in Clinical Practice* 2005;11:350-56.
39. Dranitsaris G, Maroun J and Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: A cost of illness analysis. *Supportive Care in Cancer* 2005;13:18-24.
40. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. *British Medical Journal* 2005;330:769-73.
41. Rakovitch E, Pignol JP, Chartier C, Ezer M, Verma S, Dranitsaris G, Clemons M. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. *Breast Cancer Research and Treatment* 2005;90:139-148.
42. Dranitsaris G, Maroun J and Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. *Canadian Journal of Gastroenterology* 2005;19:83-7.
43. Dranitsaris G, Kahn S, Stumpo C, et al. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. *American Journal of Cardiovascular Drugs* 2004; 2004;4:325-33.
44. Dranitsaris G, Leung PP. Using decision analysis modelling to determine pricing of new pharmaceuticals: The case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy. *International Journal of Technology Assessment in Health Care* 2004;20:289-95.

45. Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M. Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical Oncologists. *Supportive Care in Cancer* 2004;12:852-58.
46. Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kerr-Cresswell D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrell W, Dranitsaris G. Do physicians follow systemic treatment and funding policy guidelines? *Canadian Journal of Clinical Pharmacology* 2004 Spring;11:e168-78.
47. Dranitsaris G (co-author) and member of the Anemia Review Panel. Guidelines for the management of anemia. 1<sup>st</sup> ed. Toronto: MUMS Guideline Clearinghouse; 2004.
48. Dranitsaris G, Elia-Pacitti J, Cottrell C. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. *Pharmacoeconomics* 2004;22:375-87.
49. Perelman VS, Francis GJ, Rutledge T, Foote J, Martino F, Dranitsaris G. Sterile versus nonsterile gloves for repair of uncomplicated lacerations in the emergency department: A randomized controlled trial. *Annals of Emergency Medicine*. 2004;43:362-70.
50. Clemons M, Wright F, McWhirter E, Dranitsaris G. Baseline radiological staging in early breast cancer: A comparison of practice guideline recommendations with actual clinical practice. *Breast* 2003;Suppl 1:S20
51. Clemons M, Dranitsaris G, Charbonneau F, et al. How important are hematopoietic growth factors for maintaining dose intensity of adjuvant chemotherapy for breast cancer? *Current Oncology* 2003;10;1-6.
52. Dranitsaris G, Norris B, Hanna W, et al. Identifying the optimal timing of HER-2 testing in patients with breast cancer: A Canadian economic evaluation. *Current Oncology* 2003;10:36-44.
53. Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to tamoxifen. *American Journal of Clinical Oncology* 2003;23:289-96.
54. Dranitsaris G, Cottrell W, Evans WK. The cost effectiveness of chemotherapy for non-small cell lung cancer. *Current Opinion in Oncology* 2002;14:375-383.
55. Schimmer AD, Dranitsaris G, Ali V, et al. The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant. *Supportive Care in Cancer* 2002;10:247-52.
56. Dranitsaris G, Castel LD, Baladi JF, Shulman KA. Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysis. *Journal of Oncology Pharmacy Practice* 2001;7:27-33.

57. Dranitsaris G, Leung P and Warr D. Implementing evidence based guidelines in the oncology setting: results of a four-month prospective intervention study. *Supportive Carein Cancer* 2001;9:611-18.
58. Dranitsaris G, Leung P, Ciotti R, et al. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. *Pharmacoeconomics* 2001;19:955-67.
59. Dranitsaris G, Spizzirri D, Pitre M, McGeer A. A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals. *International Journal of Technology Assessment in Health Care* 2001;17:171-80.
60. Dranitsaris G, Leung PP, Mather J, Oza A. Cost utility analysis of second line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to megestrol acetate. *Anti-Cancer Drugs* 2000;11:591-601.
61. Dranitsaris G, Longo CJ, Grossman L. Measuring the economic value of a new insulin preparation (Humalog Mixture 25): A willingness-to-pay approach. *Pharmacoeconomics* 2000;18:275-87.
62. Dranitsaris G. The cost of blood transfusions in cancer patients: A reanalysis of a Canadian economic evaluation. *Journal of Oncology Pharmacy Practice* 2000;6:37-42.
63. Blomqvist A, Crabbé P, Dranitsaris G, Lanoie P. Final report of health impacts of green house gas mitigation measures. Climate Change and Health Economics Advisory Panel. Health Canada Publication, January 2000.
64. Leung P, Tanock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost utility analysis of chemotherapy using paclitaxel, docetaxel or vinorelbine for patients with anthracycline-resistant breast cancer. *J Clin Oncol* 1999;17:3082-90.
65. Dranitsaris G. Clinical and economic considerations of empiric antibiotic therapy of febrile neutropenia in cancer patients. *Pharmacoeconomics* 1999;16:343-53.
66. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. *Support Care Cancer* 1999;7:271-79.
67. Dranitsaris G. Pamidronate for the prevention of skeletal related events in multiple myeloma: What does the public think it's worth. *Int J Tech Assessment Health Care* 1999;15:108-22.
68. Ortega A., Dranitsaris G., Puodziunas A. What are cancer patients willing to pay for epoetin alfa: A cost-benefit analysis. *Cancer* 1998;83:2588-96.

69. Couban S, Dranitsaris G, Andreou P, et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: A Canadian perspective. *Bone Marrow Transplant* 1998;22:199-1205.
70. Dranitsaris G. Treatment of Non-Hodgkin's Lymphoma: A review. *Anti-Cancer Drugs* 1998;9:879-88.
71. Dranitsaris G. Statistical methods in clinical research: A review for pharmacists. *Journal of Oncology Pharmacy Practice* 1998;4:151-8.
72. Dranitsaris G, Phillips P, Rotstein C, et al. Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. *Pharmacoeconomics* 1998;13:509-18.
73. Dranitsaris G, MacDonald K, McGeer A. The rational use of antibiotics: The Princess Margaret Hospital experience: *Can J Infect Dis* 1998; 9: 41-2.
74. Ortega A, Dranitsaris G, Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. *Int J Tech Assessment Health Care* 1998; 14: 788-98.
75. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: An assessment of amifostine cytoprotection. *Support Care Cancer* 1997;5:489-99.
76. Ortega A, Dranitsaris G, Sturgeon J, et al. Cost utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. *Gynecol Oncol* 1997;66:454-63.
77. Dranitsaris G, Altmayer C, Quirt I. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor in CHOP chemotherapy for Non-Hodgkin's Lymphoma. *Pharmacoeconomics* 1997;11:566-577.
78. Dranitsaris G. G-CSF in the community setting: Oncology agent offers opportunity for community pharmacists. *Pharmacy Practice* 1996;12:79-84.
79. Dranitsaris G. Managing drug costs in the oncology setting: A possible solution to decreased funding for hospitals. *Oncology Advisor* 1996;3:3-4.
80. Dranitsaris G, Tran TM. Economic analyses of toxicity secondary to anthracycline based breast cancer chemotherapy. *European Journal of Cancer* 1995;31A:2174-80.
81. Dranitsaris G, DeAngelis C, Warr D, Narine L. Pharmacoeconomic analysis of prophylactic treatments for emesis secondary to breast cancer chemotherapy. *Canadian Journal of Hospital Pharmacy* 1995;48:266-75.

82. Dranitsaris G, Warr D, Puodziunas A. A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. *Supportive Care in Cancer* 1995;3:183-89.
83. Dranitsaris G., Tran TM, McGeer AJ, Narine L. Pharmacoeconomic analysis of empiric therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. *Pharmacoeconomics* 1995;7:49-62.
84. Dranitsaris G, Sutcliffe SB. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. *Leukmia and Lymphoma* 1995;17:139-45.
85. Dranitsaris G. Piperacillin/tazobactam: For the management of intra-abdominal infections. *Focus on New Drugs* 1994;13:12-19.
86. Dranitsaris G, Pilla NJ, McGeer AJ. A vancomycin drug use evaluation and economic analysis in a cancer treatment centre. *Canadian Journal of Hospital Pharmacy* 1994;47:59-64.
87. Walker SE, Paton, TW, Cowan DH, Manual MA, Dranitsaris G. Bioavailability of Iron in oral ferrous sulphate preparations in healthy volunteers. *Canadian Medical Association Journal* 1989;14:543-547.
88. Walker SE, Dranitsaris G. Stability of reconstituted ceftazidime in dextrose and saline solutions. *Canadian Journal of Hospital Pharmacy* 1988;41:65-72.
89. Walker SE, Dranitsaris G. Stability of reconstituted ceftriaxone in dextrose and saline solutions. *Canadian Journal of Hospital Pharmacy* 1987;40:161-166.